Russell Investments Group Ltd. Sells 93,949 Shares of Icon Plc $ICLR

Russell Investments Group Ltd. lessened its stake in shares of Icon Plc (NASDAQ:ICLR – Free Report) by 15.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 505,249 shares of the medical research company’s stock after selling 93,949 shares during the quarter. Russell Investments Group Ltd.’s holdings in Icon were worth $85,888,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in ICLR. Trinity Street Asset Management LLP raised its position in shares of Icon by 27.1% in the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock worth $266,725,000 after acquiring an additional 327,314 shares in the last quarter. Maple Rock Capital Partners Inc. lifted its stake in shares of Icon by 257.8% during the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after purchasing an additional 864,300 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Icon by 50.8% during the first quarter. Dimensional Fund Advisors LP now owns 788,828 shares of the medical research company’s stock valued at $87,262,000 after purchasing an additional 265,858 shares in the last quarter. Sound Shore Management Inc. CT bought a new stake in Icon during the first quarter valued at about $69,379,000. Finally, Eagle Health Investments LP grew its stake in Icon by 45.1% in the first quarter. Eagle Health Investments LP now owns 358,500 shares of the medical research company’s stock valued at $39,672,000 after purchasing an additional 111,410 shares during the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on ICLR. Truist Financial boosted their target price on shares of Icon from $209.00 to $268.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. UBS Group lifted their price objective on shares of Icon from $195.00 to $236.00 and gave the stock a “neutral” rating in a research report on Thursday, October 29th. Bank of America upgraded shares of Icon from an “underperform” rating to a “neutral” rating and set a $185.00 price objective for the company in a research note on Friday, October 9th. Robert W. Baird increased their target price on shares of Icon from $210.00 to $249.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Finally, TD Cowen raised their target price on shares of Icon from $197.00 to $254.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $213.76.

View Our Latest Research Report on Icon

Icon Stock Down 2.9%

Icon stock traded down $5.86 during midday trading on Friday, reaching $194.65. The company’s stock had a trading volume of 966,542 shares, compared to its average volume of 1,245,134. The stock’s 50-day simple moving average is $179.01 and its 200-day simple moving average is $147.43. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.32 and a quick ratio of 1.32. Icon Plc has a 52-week low of $66.57 and a 52-week high of $219.04. The stock has a market capitalization of $14.90 billion, a P/E ratio of 33.50, a PEG ratio of 11.11 and a beta of 1.19.

Icon (NASDAQ:ICLR – Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.04. Icon had a return on equity of 7.73% and a net margin of 5.45%. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same quarter in the previous year, the firm earned $3.31 earnings per share. The company’s revenue was down .9% on a year-over-year basis. On average, sell-side analysts expect that Icon Plc will post 9.71 EPS for the current year.

Insider Buying and Selling

In other Icon news, CEO Barry Balfe sold 5,175 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $206.66, for a total transaction of $1,069,465.50. Following the transaction, the chief executive officer owned 9,291 shares in the company, valued at approximately $1,920,078.06. This represents a 35.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Emer Lyons sold 264 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $206.66, for a total transaction of $54,558.24. Following the transaction, the chief accounting officer owned 1,217 shares in the company, valued at $251,505.22. The trade was a 17.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 23,916 shares of company stock worth $4,512,452 over the last ninety days. Company insiders own 44.00% of the company’s stock.

Icon Company Profile

(Free Report)

ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.

Further Reading

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR – Free Report).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.